Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 20/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812197 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6217390 | 0.92 | CYP3A4 (0.80) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1815861 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL29405170 | 0.91 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Hydrochloric Acid SCHEMBL7550784 | 0.90 | CYP3A4 (0.98) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4170085 | 0.90 | CYP3A4 (0.83) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7949963 | 0.90 | CYP3A4 (0.80) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4174598 | 0.90 | CYP3A4 (0.76) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4886755 | 0.89 | CYP3A4 (0.82) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL7854644 | 0.89 | CYP3A4 (0.88) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | GLAXO GROUP LIMITED (GB) | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255358-A1 | Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases | ALPI, PYGL, PPIP5K2 | CYP3A4 215/4885CYP2C9 1357/4885CYP2D6 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.